Heather L Neville1, Kelsey Mann2, Jessica Killen3, Michael Callaghan4. 1. , BScPharm, MSc, FCSHP, is with Nova Scotia Health, Halifax, Nova Scotia. 2. , BScPharm, was, at the time of this study, with Nova Scotia Health, Halifax, Nova Scotia. 3. , BScPharm, ACPR, is with Nova Scotia Health, Halifax, Nova Scotia. 4. , BScPharm, is with Nova Scotia Health, Halifax, Nova Scotia.
Abstract
BACKGROUND: Despite ample evidence of benefit, adherence to secondary prevention medication therapy after acute coronary syndrome (ACS) is often suboptimal. Hospital pharmacists are uniquely positioned to improve adherence by providing medication education at discharge. OBJECTIVE: To determine whether a standardized counselling intervention at hospital discharge significantly improved patients' adherence to cardiovascular medications following ACS. METHODS: This single-centre, prospective, nonrandomized comparative study enrolled patients with a primary diagnosis of ACS (January 2014 to July 2015). Patients who received standardized discharge counselling from a clinical pharmacist were compared with patients who did not receive counselling. At 30 days and 1 year after discharge, follow-up patient surveys were conducted and community pharmacy refill data were obtained. Adherence was assessed using pharmacy refill data and patient self-reporting for 5 targeted medications: acetylsalicylic acid, P2Y purinoceptor 12 (P2Y12) inhibitors, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, β-blockers, and statins. Thirty-day and 1-year medication utilization, cardiovascular readmission rates, and all-cause mortality were also assessed. RESULTS: Of the 259 patients enrolled, 88 (34.0%) received discharge counselling. Medication data were obtained for 253 patients (97.7%) at 30 days and 242 patients (93.4%) at 1 year. At 1 year after discharge, there were no statistically significant differences between patients who did and did not receive counselling in terms of rates of nonadherence (11.9% versus 18.4%, p = 0.19), cardiovascular readmission (17.6% versus 22.3%, p = 0.42), and all-cause mortality (3.4% versus 4.2%, p > 0.99). Overall medication nonadherence was 2.8% (7/253) at 30 days and 16.1% (39/242) at 1 year. CONCLUSIONS: Discharge medication counselling provided by hospital pharmacists after ACS was not associated with significantly better medication adherence at 1 year. Higher-quality evidence is needed to determine the most effective and practical interventions to ensure that patients adhere to their medication regimens and achieve positive outcomes after ACS. 2021 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.
BACKGROUND: Despite ample evidence of benefit, adherence to secondary prevention medication therapy after acute coronary syndrome (ACS) is often suboptimal. Hospital pharmacists are uniquely positioned to improve adherence by providing medication education at discharge. OBJECTIVE: To determine whether a standardized counselling intervention at hospital discharge significantly improved patients' adherence to cardiovascular medications following ACS. METHODS: This single-centre, prospective, nonrandomized comparative study enrolled patients with a primary diagnosis of ACS (January 2014 to July 2015). Patients who received standardized discharge counselling from a clinical pharmacist were compared with patients who did not receive counselling. At 30 days and 1 year after discharge, follow-up patient surveys were conducted and community pharmacy refill data were obtained. Adherence was assessed using pharmacy refill data and patient self-reporting for 5 targeted medications: acetylsalicylic acid, P2Y purinoceptor 12 (P2Y12) inhibitors, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, β-blockers, and statins. Thirty-day and 1-year medication utilization, cardiovascular readmission rates, and all-cause mortality were also assessed. RESULTS: Of the 259 patients enrolled, 88 (34.0%) received discharge counselling. Medication data were obtained for 253 patients (97.7%) at 30 days and 242 patients (93.4%) at 1 year. At 1 year after discharge, there were no statistically significant differences between patients who did and did not receive counselling in terms of rates of nonadherence (11.9% versus 18.4%, p = 0.19), cardiovascular readmission (17.6% versus 22.3%, p = 0.42), and all-cause mortality (3.4% versus 4.2%, p > 0.99). Overall medication nonadherence was 2.8% (7/253) at 30 days and 16.1% (39/242) at 1 year. CONCLUSIONS: Discharge medication counselling provided by hospital pharmacists after ACS was not associated with significantly better medication adherence at 1 year. Higher-quality evidence is needed to determine the most effective and practical interventions to ensure that patients adhere to their medication regimens and achieve positive outcomes after ACS. 2021 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.
Authors: Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette K Wenger; R Scott Wright; Hani Jneid; Steven M Ettinger; Theodore G Ganiats; George J Philippides; Alice K Jacobs; Jonathan L Halperin; Nancy M Albert; Mark A Creager; David DeMets; Robert A Guyton; Frederick G Kushner; E Magnus Ohman; William Stevenson; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2013-04-29 Impact factor: 24.094
Authors: Olavo Fernandes; Sean K Gorman; Richard S Slavik; William M Semchuk; Steve Shalansky; Jean-François Bussières; Douglas Doucette; Heather Bannerman; Jennifer Lo; Simone Shukla; Winnie W Y Chan; Natalie Benninger; Neil J MacKinnon; Chaim M Bell; Jeremy Slobodan; Catherine Lyder; Peter J Zed; Kent Toombs Journal: Ann Pharmacother Date: 2015-03-16 Impact factor: 3.154
Authors: John A Spertus; Richard Kettelkamp; Clifton Vance; Carole Decker; Philip G Jones; John S Rumsfeld; John C Messenger; Sanjaya Khanal; Eric D Peterson; Richard G Bach; Harlan M Krumholz; David J Cohen Journal: Circulation Date: 2006-06-12 Impact factor: 29.690
Authors: Sara Bristol Calvert; Judith M Kramer; Kevin J Anstrom; Lisa A Kaltenbach; Judith A Stafford; Nancy M Allen LaPointe Journal: Am Heart J Date: 2012-04 Impact factor: 4.749
Authors: Ulrika Gillespie; Anna Alassaad; Dan Henrohn; Hans Garmo; Margareta Hammarlund-Udenaes; Henrik Toss; Asa Kettis-Lindblad; Håkan Melhus; Claes Mörlin Journal: Arch Intern Med Date: 2009-05-11
Authors: P Michael Ho; Anne Lambert-Kerzner; Evan P Carey; Ibrahim E Fahdi; Chris L Bryson; S Dee Melnyk; Hayden B Bosworth; Tiffany Radcliff; Ryan Davis; Howard Mun; Jennifer Weaver; Casey Barnett; Anna Barón; Eric J Del Giacco Journal: JAMA Intern Med Date: 2014-02-01 Impact factor: 21.873
Authors: Rajiv Chowdhury; Hassan Khan; Emma Heydon; Amir Shroufi; Saman Fahimi; Carmel Moore; Bruno Stricker; Shanthi Mendis; Albert Hofman; Jonathan Mant; Oscar H Franco Journal: Eur Heart J Date: 2013-08-01 Impact factor: 29.983
Authors: Thang Nguyen; Thao H Nguyen; Phu T Nguyen; Ha T Tran; Ngoc V Nguyen; Hoa Q Nguyen; Ban N Ha; Tam T Pham; Katja Taxis Journal: Front Pharmacol Date: 2018-06-21 Impact factor: 5.810